Review: the spectrum of antimicrobial resistance in bacteria isolated from wounds of patients with epidermolysis bullosa

References

• Bardhan A, et al. Epidermolysis bullosa. Nature Rev Dis Primers. 2020;6:78.
   PubMed Web of Science ®Google Scholar
• Hon KL, Chu S, Leung AKC. Epidermolysis bullosa: pediatric perspectives. Curr Pediatr Rev. 2022;18(3):182–190. doi:10.2174/1573396317666210525161252.
   PubMed Web of Science ®Google Scholar
• Marchili MR, Spina G, Roversi M, et al. Epidermolysis Bullosa in children: the central role of the pediatrician. Orphanet J Rare Dis. 2022;17(1):147. doi:10.1186/s13023-021-02144-1.
   PubMed Web of Science ®Google Scholar
• El Hachem M, Giancristoforo S, Diociaiuti A. Inherited epidermolysis bullosa. Ital J Dermatol Venereol. 2014;149:651–662.
   Google Scholar
• Singer HM, Levin LE, Garzon MC, et al. Wound culture isolated antibiograms and caregiver-reported skin care practices in children with epidermolysis bullosa. Pediatr Dermatol. 2018;35(1):92–96. doi:10.1111/pde.13331.
   PubMed Web of Science ®Google Scholar
• Brandling-Bennett HA, Morel KD. Common wound colonizers in patients with epidermolysis bullosa. Pediatr Dermatol. 2010;27(1):25–28. doi:10.1111/j.1525-1470.2009.01070.x.
   PubMed Web of Science ®Google Scholar
• Levin LE, Shayegan LH, Lucky AW, et al. Characterization of wound microbes in epidermolysis bullosa: results from the epidermolysis bullosa clinical characterization and outcomes database. Pediatr Dermatol. 2021;38(1):119–124. doi:10.1111/pde.14444.
   PubMed Web of Science ®Google Scholar
• Santin JT, Mariath LM, Rossato AM, et al. Prevalence and antimicrobial resistance profile of Staphylococcus aureus in inherited epidermolysis bullosa: a cross-sectional multicenter study in Brazil. Int J Dermatol. 2021;60(9):1126–1130. doi:10.1111/ijd.15634.
   PubMed Web of Science ®Google Scholar
• Fine J-D. Epidemiology of Inherited Epidermolysis Bullosa Based on Incidence and Prevalence Estimates From the National Epidermolysis Bullosa Registry. JAMA Dermatol. 2016;152(11):1231–1238. doi:10.1001/jamadermatol.2016.2473.
   PubMed Web of Science ®Google Scholar
• Kho YC, Rhodes LM, Robertson SJ, et al. Epidemiology of epidermolysis bullosa in the antipodes: the australasian epidermolysis bullosa registry with a focus on herlitz junctional epidermolysis bullosa. Arch Dermatol. 2010;146(6):635–640. doi:10.1001/archdermatol.2010.109.
   PubMedGoogle Scholar
• Agero AL, Rhodes L, Murrell DF. The Australasian Epidermolysis Bullosa Registry (AEBR). J Am Acad Dermatol. 2008;58(2):AB86. doi:10.1016/j.jaad.2007.10.382.
   Web of Science ®Google Scholar
• Mellerio JE. Infection and colonization in epidermolysis bullosa. Dermatol Clin. 2010;28(2):267–269, ix. doi:10.1016/j.det.2010.01.004.
   PubMed Web of Science ®Google Scholar
• van der Kooi-Pol MM, Duipmans JC, Jonkman MF, et al. Host–pathogen interactions in epidermolysis bullosa patients colonized with Staphylococcus aureus. Int J Med Microbiol. 2014;304(2):195–203. doi:10.1016/j.ijmm.2013.11.012.
   PubMed Web of Science ®Google Scholar
• Høiby N, Bjarnsholt T, Givskov M, et al. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents. 2010;35(4):322–332. doi:10.1016/j.ijantimicag.2009.12.011.
   PubMed Web of Science ®Google Scholar
• Malone M, Radzieta M, Jensen SO, et al. Wound biofilms and their role in individuals with epidermolysis bullosa. Australas J Dermatol. 2020;61(3):279–280. doi:10.1111/ajd.13274.
   PubMed Web of Science ®Google Scholar
• Rather MA, Gupta K, Mandal M. Microbial biofilm: formation, architecture, antibiotic resistance, and control strategies. Braz J Microbiol. 2021;52(4):1701–1718. doi:10.1007/s42770-021-00624-x.
   PubMed Web of Science ®Google Scholar
• Roy R, Tiwari M, Donelli G, et al. Strategies for combating bacterial biofilms: a focus on anti-biofilm agents and their mechanisms of action. Virulence. 2018;9(1):522–554. doi:10.1080/21505594.2017.1313372.
   PubMed Web of Science ®Google Scholar
• Bjarnsholt T, Kirketerp-Møller K, Kristiansen S, et al. Silver against pseudomonas aeruginosa biofilms. APMIS. 2007;115(8):921–928. doi:10.1111/j.1600-0463.2007.apm_646.x.
   PubMed Web of Science ®Google Scholar
• Bridier A, Dubois-Brissonnet F, Boubetra A, et al. The biofilm architecture of sixty opportunistic pathogens deciphered using a high throughput CLSM method. J Microbiol Methods. 2010;82(1):64–70. doi:10.1016/j.mimet.2010.04.006.
   PubMed Web of Science ®Google Scholar
• Kaushik A, Kest H, Sood M, et al. Biofilm producing Methicillin-Resistant Staphylococcus aureus (MRSA) Infections in Humans: clinical Implications and Management. Pathogens. 2024;13(1):76. doi:10.3390/pathogens13010076.
   PubMed Web of Science ®Google Scholar
• Silva V, Almeida L, Gaio V, et al. Biofilm formation of multidrug-resistant MRSA strains isolated from different types of human infections. Pathogens. 2021;10(8):970. doi:10.3390/pathogens10080970.
   PubMed Web of Science ®Google Scholar
• Otto M. Staphylococcal biofilms. Curr Top Microbiol Immunol. 2008;322:207–228. doi:10.1007/978-3-540-75418-3_10.
   PubMed Web of Science ®Google Scholar
• Schilcher K, Horswill AR. Staphylococcal biofilm development: structure, regulation, and treatment strategies. Microbiol Mol Biol Rev. 2020;84(3):e00026-19. doi:10.1128/mmbr.00026-00019.
   PubMed Web of Science ®Google Scholar
• Leshem T, Schnall B-S, Azrad M, et al. Incidence of biofilm formation among MRSA and MSSA clinical isolates from hospitalized patients in Israel. J Appl Microbiol. 2022;133(2):922–929. doi:10.1111/jam.15612.
   PubMed Web of Science ®Google Scholar
• Mirghani R, Saba T, Khaliq H, et al. Biofilms: formation, drug resistance and alternatives to conventional approaches. AIMS Microbiol. 2022;8(3):239–277. doi:10.3934/microbiol.2022019.
   PubMed Web of Science ®Google Scholar
• García-Espinosa L, Del Rosal T, Quintana L, et al. Bloodstream infection in children with epidermolysis bullosa. Pediatr Infect Dis J. 2023;42(6):510–514. doi:10.1097/INF.0000000000003871.
   PubMed Web of Science ®Google Scholar
• Graber CJ, Shane AL, Weintrub P, et al. Clonality of staphylococcus aureus colonization over time in attendees of a camp for children with chronic dermatoses. Pediatr Dermatol. 2011;28(5):519–523. doi:10.1111/j.1525-1470.2011.01508.x.
   PubMed Web of Science ®Google Scholar
• van der Kooi-Pol MM, Veenstra-Kyuchukova YK, Duipmans JC, et al. High genetic diversity of Staphylococcus aureus strains colonizing patients with epidermolysis bullosa. Exp Dermatol. 2012;21(6):463–466. doi:10.1111/j.1600-0625.2012.01502.x.
   PubMed Web of Science ®Google Scholar
• Busani S, Serafini G, Mantovani E, et al. Mortality in patients with septic shock by multidrug resistant bacteria: risk factors and impact of sepsis treatments. J Intensive Care Med. 2019;34(1):48–54. doi:10.1177/0885066616688165.
   PubMed Web of Science ®Google Scholar
• Capsoni N, Bellone P, Aliberti S, et al. Prevalence, risk factors and outcomes of patients coming from the community with sepsis due to multidrug resistant bacteria. Multidiscip Respir Med. 2019;14(1):23. doi:10.4081/mrm.2019.23.
   PubMedGoogle Scholar
• Antonov NK, Garzon MC, Morel KD, et al. High prevalence of mupirocin resistance in Staphylococcus aureus isolates from a pediatric population. Antimicrob Agents Chemother. 2015;59(6):3350–3356. doi:10.1128/AAC.00079-15.
   PubMed Web of Science ®Google Scholar
• Lee AS, Macedo-Vinas M, François P, et al. Trends in mupirocin resistance in meticillin-resistant < em > Staphylococcus aureus</em > and mupirocin consumption at a tertiary care hospital. J Hosp Infect. 2011;77(4):360–362. doi:10.1016/j.jhin.2010.11.002.
   PubMed Web of Science ®Google Scholar
• Hou P-C, Wang H-T, Abhee S, et al. Investigational treatments for epidermolysis bullosa. Am J Clin Dermatol. 2021;22(6):801–817. doi:10.1007/s40257-021-00626-3.
   PubMed Web of Science ®Google Scholar
• Pope E, Lara-Corrales I, Mellerio J, et al. A consensus approach to wound care in epidermolysis bullosa. J Am Acad Dermatol. 2012;67(5):904–917. doi:10.1016/j.jaad.2012.01.016.
   PubMed Web of Science ®Google Scholar
• Maxson T, Mitchell DA. Targeted treatment for bacterial infections: prospects for pathogen-specific antibiotics coupled with rapid diagnostics. Tetrahedron. 2016;72(25):3609–3624. doi:10.1016/j.tet.2015.09.069.
   PubMed Web of Science ®Google Scholar
• Salavastru CM, Sprecher E, Panduru M, et al. Recommended strategies for epidermolysis bullosa management in romania. Maedica (Bucur). 2013;8(2):200–205.
   PubMedGoogle Scholar
• Langan SM, Williams HC. A systematic review of randomized controlled trials of treatments for inherited forms of epidermolysis bullosa. Clin Exp Dermatol. 2009;34(1):20–25. doi:10.1111/j.1365-2230.2008.02789.x.
   PubMed Web of Science ®Google Scholar
• Lara-Corrales I, Parkin PC, Stephens D, et al. The efficacy of trimethoprim in wound healing of patients with epidermolysis bullosa: a feasibility trial. J Am Acad Dermatol. 2012;66(2):264–270. doi:10.1016/j.jaad.2010.01.047.
   PubMed Web of Science ®Google Scholar
• Hammersen J, Neuner A, Wild F, et al. Attenuation of severe generalized junctional epidermolysis bullosa by systemic treatment with gentamicin. Dermatology. 2019;235(4):315–322. doi:10.1159/000499906.
   PubMed Web of Science ®Google Scholar
• Mosallaei D, Hao M, Antaya RJ, et al. Molecular and clinical outcomes after intravenous gentamicin treatment for patients with junctional epidermolysis bullosa caused by nonsense variants. JAMA Dermatol. 2022;158(4):366–374. doi:10.1001/jamadermatol.2021.5992.
   PubMed Web of Science ®Google Scholar
• Shayegan LH, Levin LE, Galligan ER, et al. Skin cleansing and topical product use in patients with epidermolysis bullosa: results from a multicenter database. Pediatr Dermatol. 2020;37(2):326–332. doi:10.1111/pde.14102.
   PubMed Web of Science ®Google Scholar